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Abstract
Background: Acinetobacter baumannii is an important hospital-acquired pathogen in healthcare facilities that
frequently causes bacteraemia and ventilator-associated pneumonia in intensive care units. Acinetobacter baumannii
can be isolated from various sites in the hospital environment like medical equipment, bed linen, medical personnel
and indwelling catheters. It is difficult to treat A. baumannii infections because of their highly resistant antimicrobial
profiles. The purpose of this study was to determine the prevalence of β-lactamase genes in multidrug-resistant (MDR)
clinical A. baumannii isolates using Multiplex-PCR (M-PCR) assays.
Methods: One hundred MDR A. baumannii isolates were collected from the diagnostic division of the Department of
Medical Microbiology after routine analysis of the submitted specimens. All collected isolates were identified and tested
for susceptibility using the VITEK 2® system (bioMérieux, France). Six isolates were excluded from this study because the
isolates were incorrectly identified as A. baumannii with the VITEK 2® system (bioMérieux, France). Molecular tests, namely
M-PCR assays, pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) were performed. MLST
analyses were performed on representative isolates from the four major pulsotypes (≥5 isolates with 80 % similarity) and
selective isolates from each minor pulsotype.
Results: All the A. baumannii isolates showed 100 % resistance to ampicillin, amoxicillin, cefuroxime, cefuroximine axetil,
cefoxitin, cefotaxime and nitrofurantoin. Seven percent of the isolates were resistant to amikacin. Two percent of the
isolates were classified as having intermediate susceptibility to tigecycline. A. baumannii isolates showed an antibiotic
resistance profile of 67 % and higher to antibiotics, such as ceftazidime, cefepime, imipenem, meropenem, gentamicin,
ciprofloxacin and trimethoprim/sulfamethoxazole. None of the isolates were resistant to colistin. The M-PCR assays
showed that 99 % of the isolates contained the OXA-51 gene and 77 % contained the OXA-23 gene. None of the
isolates contained the GES, GIM, IMP, KPC, NDM, OXA-24, OXA-58, PER, SIM, SPM, VEB and VIM genes. Representative A.
baumannii isolates were grouped into five existing sequence types (ST): ST106, ST258, ST339, ST502, ST758 and ST848.
Isolates belonging to the pan-European clonal lineages I and II (EUI and EUII) were identified.
Conclusion: The high prevalence of MDR A. baumannii isolates has a severe impact on available treatment choices and
this in return impacts on treatment outcomes in the studied healthcare facilities. The most dominant ST among the
collected isolates was ST758, member of the EUI group. The presence of the OXA-23 gene was not restricted to a
specific ST. Continuous research and surveillance is necessary to monitor the circulating β-lactamase genes in clinical
settings to guide infection control policies in order to try and curb the spread of this bacterium.
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Background
Acinetobacter baumannii is an emerging opportunistic
pathogen that can become resistant to multiple anti-
microbial agents [1–3]. Over the past 20 years A. bau-
mannii’s clinical importance has been driven by its
ability to obtain antimicrobial resistance factors [4, 5].
Resistance is acquired through the transfer of integrons,
plasmids or transposons that carry groups of genes en-
coding resistance to several antibiotic families [6]. This
bacterium can survive under a wide range of environ-
mental conditions and on surfaces for extended periods
of time and this can lead to both endemicity and out-
breaks in healthcare facilities [4, 7].
Major problems are caused by this pathogen, espe-
cially among critically ill hospitalised patients in inten-
sive care units (ICU’s) [5, 6, 8]. Clinical manifestations
that can be associated with A. baumannii include:
bacteraemia, meningitis, pneumonia, urinary tract infec-
tion, ventilator-associated pneumonia (VAP) and wound
infections [8–10]. Patients with underlying chronic
disease, decreased immunity, indwelling catheters and
prolonged hospitalisation are more at risk to become
colonised and develop subsequent infection with A.
baumannii [7–9, 11].
This pathogen possesses different antimicrobial resist-
ance mechanisms, which include the enzymatic inactiva-
tion of β-lactam antibiotics (cephalosporins, carbapenems
and monobactams) through the production of extended
spectrum β-lactamases, carbapenemases and AmpC-type
(ampicillin class C) enzymes [12–15]. The β-lactamases of
Gram-negative bacteria belong to Ambler classes A to D
[12, 13]. The inherent class D oxacillinases (OXA) of A.
baumannii belong to the chromosomally encoded OXA-
51-like enzyme group [16–18]. However, the OXA-51
enzyme has been under considerable pressure due to anti-
biotic use and has evolved and now plays an important
role in the carbapenem resistance of A. baumannii isolates
[19]. If ISAbaI is located upstream of the blaOXA genes the
A. baumannii isolate will have an increased OXA-51 ex-
pression which leads to carbapenem resistance (imipenem
and meropenem) [19–21].
Infections caused by A. baumannii are difficult to
treat because of the resistance to antimicrobial agents,
especially β-lactams [3, 22]. There have been reports of
MDR A. baumannii from hospitals all around the world
(Argentina, Brazil, China, Europe and the United
Kingdom) [4, 23, 24]. Only a few antimicrobial agents
namely colistin (in combination with carbapenems) and
tigecycline are available for the treatment of MDR A.
baumannii [1, 2, 15]. However, there are now reports of
colistin resistance in A. baumannii isolates, which is of
great concern as colistin plays a pivotal role in MDR A.
baumannii treatment [25–28]. Fortunately colistin re-
sistance in A. baumannii is still rare [21, 25].
The aim of this study was to detect the prevalence of
β-lactamase genes and to determine the genetic rela-
tionship among the A. baumannii isolates circulating in
our clinical setting. The prevalence of β-lactamase genes
is important for the surveillance of circulating A. bau-
mannii strains as it provides more information for the
infection control policies of the hospitals.
Methods
Study design and setting
The quantitative study was aimed to determine the
prevalence of β-lactamase genes in consecutively col-
lected A. baumannii isolates obtained from clinical
specimens and to determine the genetic relatedness of
circulating strains. The study was conducted at the
Department of Medical Microbiology, Prinshof Campus,
University of Pretoria/National Health Laboratory Service
(NHLS) and received ethical approval from the Research
Ethics Committee, Faculty of Health Sciences, University
of Pretoria (121/2013); a waiver for informed consent
was provided.
Collection, culturing and storage of A. baumannii clinical
isolates
One hundred consecutive clinical A. baumannii iso-
lates were collected without prior knowledge of pa-
tient information, hospital ward, specimen type and
antibiotic susceptibility status. All 100 A. baumannii
isolates were collected from the diagnostic laboratory
during May to July 2013. The laboratory processes
specimens from a tertiary academic hospital as well
as district hospitals and various clinics as part of
standard care. Routine analysis was performed as re-
quested on the form and according to sample type.
The isolates were identified and tested for susceptibility
using the automated VITEK® 2 system (BioMérieux,
France) with the VITEK® 2 GN card and the VITEK®
2 AST-N255 card. Gender, age, type of specimen,
hospital, ward and the antibiotic susceptibility profiles
were collected.
One colony of an isolate (obtained from a blood agar
plate) was inoculated into 5 ml tryptone soya broth
(TSB) (Oxoid, UK) and incubated on a shaking incuba-
tor (Vacutec, South Africa) at 35°C for a period of 18 to
24 h. Growth was indicated by turbidity in the broth.
Isolates were stored by adding 900 μl of 50% glycerol
(Merck, Germany) to 900 μl of the overnight TSB cul-
ture (Oxoid, UK) in 2 ml cryotubes (Greiner Bio-One,
Germany) in a one to one ratio. This was done in tripli-
cate and the isolates were stored in a -80°C freezer
(New Brunswick, USA). The quality control strains
used were the multidrug resistant A. baumannii ATCC®
BAA-1605 strain; Klebsiella pneumoniae ATCC 8303
and K. pneumoniae ATCC BAA-2146.
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DNA extraction of A. baumannii isolates
The genomic DNA of each of the 100 A. baumannii
isolates was extracted from a single colony grown in
TSB (Oxoid, UK) culture media by using the ZR Fun-
gal/Bacterial kit [29]. The manufacturer’s instructions
were followed with some modifications; instead of 50 to
100 mg of cells, 1 000 μl of overnight broth was used, cen-
trifuged (Eppendorf 5417C, Germany) and the pellet was
resuspended in phosphate buffered saline (PBS) solution
(pH 7.2, Gibco® PBS, Life Technologies Corporation, USA)
and 600 μl of the lysis solution were used instead of the
prescribed 750 μl. The extracted genomic DNA was stored
at -20 °C (Defy Ltd, Multimode, SA) until further analysis.
The detection of β-lactamase genes in A. baumannii by
using M-PCR assays
Multiplex PCR assays were performed by using the
QIAGEN® M-PCR kit (QIAGEN®, Germany) for the de-
tection of several antibiotic resistance genes in A. bau-
mannii (Table 1). An initial denaturation step of 95 °C for
15 min, followed by 30 cycles of denaturation at 94 °C for
30 s, an annealing temperature dependent on the melting
temperature of the primer pair (multiplex I: 52 °C; multi-
plex II and III: 57 °C and multiplex IV: 60 °C) and exten-
sion at 72 °C for 90 s, followed by the final extension step
at 70 °C for 10 min. A negative control (sterile ultrapure
water) was included for all M-PCR assays. The follow-
ing positive controls were used for multiplex I to IV: A.
baumannii ATCC® BAA-1605™ strain; K. pneumoniae
ATCC 8303 [Klebsiella pneumoniae carbapenemase
(KPC) positive control] and K. pneumoniae ATCC
BAA-2146 [New Delhi metallo-β-lactamase (NDM)
positive control]. All isolates testing negative for the
presence of the inherent OXA-51 gene were sent for
identification using matrix assisted laser desorption
time of flight mass spectrometry (MALDI-TOF).
Analysis of the Multiplex PCR products
A 1.8 % (m/v) MetaPhor agarose gel (Lonza, USA) with
5 μl of ethidium bromide (EtBr) (10 μg.ml−1) (Promega,
USA) was used to visualise the PCR products after gel
electrophoresis (Bio-Rad, USA). The 1.8 % (m/v) MetaPhor®
agarose gel was prepared according to the manufacturer’s
instructions (Lonza, USA).
A ready-to-use 100 bp DNA ladder (Fermentas, Thermo-
Scientific, USA) was used to determine the approximate
sizes of the amplicons. Gel electrophoresis (Bio-Rad,
Germany) was performed at 90 V for 100 min with 1x
Tris-Borate-EDTA (TBE) buffer [40 mM Tris-HCl, 20 mM
Boric acid (Sigma-Aldrich, USA) and 1 mM EDTA (Sigma-
Aldrich, USA), pH 8.0]. The bands were visualised and
captured using a UVP Doc It transilluminator (Ultra-violet
Products Incorporated, USA).
Determination of the genetic relationship of clinical
A. baumannii isolates using the PFGE assay
The Pulsenet PFGE protocol [30] was followed with some
modifications. The optical density (OD) was measured at
630 nm. The absorbance was adjusted to an OD range of
1.4 to 1.6 by using the ELx800 absorbance microplate
reader (Bio-TEK, USA). The plugs were incubated over-
night at 51°C and after incubation the plug was transferred
to a new BD falcon tube (BD Biosciences, USA). The ApaI
enzyme (New England Biolabs, USA) was used and the
Salmonella choleraesuis serovar Braenderup (ATCC BAA-
664) was used as a marker. Gel electrophoresis was
performed using the following set conditions: interval 25
linear 5; angle 120° constant; voltage 220 V linear to 200 V
and ran for 24 h. After the PFGE run was completed,
the 1.2 % (m/v) SeaKem® LE agarose (Lonza, USA) gel
was stained in 1 L distilled water, containing 250 μl
EtBr (10 μg.ml-1) for 15 min and was destained in dis-
tilled water for 30 min. The gel was viewed and docu-
mented with a UV Doc It transilluminator (Ultra-violet
Products Incorporated, USA). The banding patterns
were analysed using the GelCompar II software
programme (Applied Maths, Belgium). A distance matrix
was constructed using the Dice coefficient and a dendo-
gramme was constructed using the unweighted pair group
method with arithmetic mean (UPGMA) [31]. Pulsotype
designation was based on isolates showing ≥80 % related-
ness, which corresponds to the Tenover criteria of possibly
related 4 to 6 band differences between isolates [32, 33].
Representatives from each major PFGE pulsotype (≥5
isolates) and selective minor pulsotypes (< 5 isolates)
with ≥80 % similarity were chosen for MLST analyses.
Molecular epidemiology
Seven housekeeping genes were used for MLST which in-
cluded the following genes: (i) citrate synthase (gltA); (ii)
DNA gyrase subunit B (gyrB); (iii) glucose dehydrogenase
B (gdhB); (iv) homologous recombination factor (recA); (v)
60-kDa chaperonin (cpn60); (vi) glucose-6-phosphate
isomerase (gpi) and (vii) RNA polymerase sigma factor
(rpoD) (http://pubmlst.org/abaumannii/info/primers_-
Oxford.shtml). All the primers were synthesised by Inqaba
Biotechnical Industries, South Africa.
All seven housekeeping genes were individually ampli-
fied in a 50 μl reaction as described in the Bioline kit’s
guideline (Bioline, UK). The following programme was
used on the thermal cycler (G-storm Model GS4822,
Labtech, UK): an initial denaturation step of 94 °C for 2
min, followed by 35 cycles of denaturation at 94 °C for 30
s, an annealing temperature at 50 °C for 30 s, extension at
72 °C for 30 s, followed by the final extension step at 72 °C
for 5 min [34]. The amplicons were visualised on a 1.8 %
(m/v) MetaPhor agarose gel (Lonza, USA) as described
previously. All the amplicons were sequenced in both
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forward and reverse directions by Inqaba Biotechnical In-
dustries, South Africa. An ABI file obtained for each se-
quence were analysed with the CLC Main Workbench
Version 6.0 (CLCbio, USA). The sequences were assigned
to corresponding allelic profiles and sequence types by
using the MLST Oxford database (http://pubmlst.org/
abaumannii/).
Data analysis
One hundred consecutive A. baumannii isolates were col-
lected, which were identified by the automated VITEK® 2
system (BioMérieux, France). Six isolates were excluded
from this study because the isolates were incorrectly identi-
fied as A. baumannii by the VITEK® 2 system. These iso-
lates were identified by MALDI-TOF analysis as: A. pittii;
K. pneumoniae; Pseudomonas putida (2x); Staphylococcus
aureus and S. epidermidis.
The results are reported on 94 clinical A. baumannii
isolates. The proportions of A. baumannii isolates with
Ambler classes A, B and D resistance genes were deter-
mined for the 94 isolates. The results were reported as
proportions or percentages along with 95 % confidence
Table 1 Oligonucleotide primer sequences used for the detection of β-lactamases in four Multiplex PCR assays of A. baumannii
clinical isolates
Target Primer name Primer sequence (5’ to 3’)a Amplicon size (bp) Reference
Multiplex I:
OXA-23 blaOXA-23 (F) GATCGGATTGGAGAACCAGA 501 [51]
blaOXA-23 (R) ATTTCTGACCGCATTTCCAT
OXA-24 blaOXA-24 (F) GGTTAGTTGGCCCCCTTAAA 246
blaOXA-24 (R) AGTTGAGCGAAAAGGGGATT
OXA-51 blaOXA-51 (F) TAATGCTTTGATCGGCCTTG 353
blaOXA-51 (R) TGGATTGCACTTCATCTTGG
OXA-58 blaOXA-58 (F) AAGTATTGGGGCTTGTGCTG 599
blaOXA-58 (R) CCCCTCTGCGCTCTACATAC
Multiplex II:
VIM blaVIM (F) GATGGTGTTTGGTCGCATA 390 [52]
blaVIM (R) CGAATGCGCAGCACCAG
KPC blaKPC (F) CATTCAAGGGCTTTCTTGCTGC 538
blaKPC (R) ACGACGGCATAGTCATTTGC




GES blaGES (F) AGTCGGCTAGACCGGAAAG 399 [52]
blaGES (R) TTTGTCCGTGCTCAGGAT
PER blaPER (F) GCTCCGATAATGAAAGCGT 520
blaPER (R) TTCGGCTTGACTCGGCTGA
VEB blaVEB (F) CATTTCCCGATGCAAAGCGT 648
blaVEB (R) CGAAGTTTCTTTGGACTCTG
Multiplex IV:
GIM blaGIM (F) CGTTGCCAGCTTTAGCTCAGG 279 [53]
blaGIM (R) GCAACTTGATACCAGCAGTGCG
SPM blaSPM (F) GGGTGGCTAAGACTATGAAGCC 447
blaSPM (R) GCCGCCGAGCTGAATCGG
SIM-1 blaSIM (F) TTGCGGAAGAAGCCCAGCCAG 613
blaSIM (R) GCGTCTCCGATTTCACTGTGGC
NDM – 1 blaNDM-1(F) CCCGGCCACACCAGTGACA 129
blaNDM-1(R) GTAGTGCTCAGTGTCGGCAT
aAll oligonucleotides were synthesised and purified by Inqaba Biotechnical Industries, South Africa
bY = T or C; D = A or G or T
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intervals for the given sample size with an accuracy of
within 10 %. The antimicrobial susceptibility and geno-
typic results obtained in this study were compared to a
study done in 2008 in the same clinical setting [5]. The
antimicrobial susceptibility profiles were also compared
to the surveillance data from 12 sentinel public hospitals
in South Africa (SA) [35].
Results
Collection of A. baumannii clinical isolates
Fifty-eight of the isolates were collected from male pa-
tients and 36 isolates were collected from female patients.
Forty-three percent of the isolates were collected from di-
verse sites, 4 % from urine, 41 % from sputum and 12 %
from blood cultures. The mean age of the patients was
39 years (ranging from 4 days to 77 years). A. baumannii
was isolated from various wards but was the most preva-
lent in the medical and pulmonology ICU (12 %). Age and
sex is not a cofounder and hence the odds ratio for area
need not be adjusted. The crude odds ratio is 1.61 with a
95 % confidence interval (0.60; 4.31) and is not significant
(p = 0.345).
Susceptibility profiles of A. baumannii isolates using the
VITEK 2® system
All 94 of the A. baumannii isolates were resistant to ampi-
cillin, amoxicillin, cefuroxime, cefuroximine axetil, cefoxi-
tin, cefotaxime and nitrofurantoin. The A. baumannii
isolates showed high level carbapenem and cephalosporin
resistance (imipenem 86 %; meropenem 86 %; cefepime
90 % and ceftazidime 89 %). Table 2 shows the antimicro-
bial susceptibility profiles of the collected 94 A. baumannii
isolates.
The 94 A. baumannii isolates showed an increase in
antimicrobial resistance profiles compared to the study
done by Kock et al. [5] in 2008: imipenem were 59 % in
2008 and 86 % in 2013 and meropenem were 63 % in
2008 and 86 % in 2013. The cephalosporin resistance
patterns changed as follows: cefepime were 62 % in
2008 and were 90 % in 2013; ceftazidime were 45 % in
2008 and 89 % in 2013. Figure 1 shows the overall per-
centage of resistance in 2008 and 2013 in the Pretoria
region. Data from the communicable diseases surveil-
lance bulletin [35] showed that the A. baumannii iso-
lates collected in 2013 in public hospitals in SA have
resistance towards carbapenems and cephalosporins
(imipenem 77 %; cefepime 80 % and ceftazidime 73 %).
Molecular identification of resistance genes found in
A. baumannii isolates using M-PCR assays
The M-PCR I assay showed that 99 % of the isolates con-
tained the OXA-51 gene and 77 % contained the OXA-23
gene. None of the isolates were positive for OXA-24/40
and OXA-58. Figure 2 illustrates the M-PCR I assay, which
targeted the OXA-23 (501 bp), OXA-24/40 (246 bp),
OXA-51 (353 bp) and OXA-58 (599 bp) genes.
The results of the M-PCR assay I revealed the pres-
ence of two resistant profile types of A. baumannii that
were circulating in the studied clinical setting. Type 1
was positive for both OXA-51 and OXA-23 (77 %) and
type 2 was only positive for OXA-51 (22 %).
The M-PCR assay II [Imipenem metallo-β-lactamase
(IMP), KPC and Verona integrin-encoded metallo-β-
lactamase (VIM) genes]; III [Guyana extended-spectrum β-
lactamase (GES), Pseudomonas extended resistance (PER)
and Vietnam extended-spectrum β-lactamase (VEB) genes]
and IV [German imipenemase (GIM), NDM-1, Seoul
imipenem metallo-β-lactamase (SIM-1) and Sao Paulo
metallo-β-lactamase (SPM) genes] were negative for all the
tested genes.
Determination of the genetic relationship and global
epidemiology of clinical A. baumannii isolates
The PFGE analysis showed that the 94 A. baumannii iso-
lates can be grouped into four major pulsotypes (includes ≥
5 isolates) and several minor pulsotypes (< 5 isolates)
(Fig. 3). The representative A. baumannii isolates from each
major pulsotype and selected minor pulsotypes were
grouped into five existing STs (ST106, 1-1-1-1-1-98-6;
ST258, 1-15-8-10-28-110-32; ST339, 44-73-4-11-44-121-4;
ST502, 1-12-3-2-2-100-3; ST758, 1-17-8-10-28-106-32 and
ST848, 1-15-3-2-2-142-3). Two groups (EUI: ST258,
ST758; EUII: ST502, ST848) and singletons (ST106,
ST339) which shared five out of seven alleles were identi-




The increase in resistance profiles of A. baumannii can
be due to the misuse of antibiotics in clinical settings, or
because of patients who do not complete the prescribed
antibiotic course. The blaOXA genes have an impact on
treatment because it can already be resistant to the new
inhibitors, such as β-lactamase inhibitors, or it can rap-
idly gain resistance [19].
The ability of the OXA β-lactamases to confer carba-
penem resistance has already had a huge impact on the
ability to treat Gram-negative pathogens and the current
situation suggests that the problem is only set to in-
crease [19]. The advantage of using molecular tests, such
as the M-PCR assays used in this study, is that resistance
genes circulating in clinical settings can be determined
as this is not possible with phenotypic tests. Through
molecular methods this study has indicated that 99 % of
the A. baumannii isolates contained the OXA-51 gene,
compared to Kock et al. [5] where only 81% out of the
97 isolates contained this gene. In the Kock et al. [5]
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study, the species identification obtained by the VITEK® 2
system was not confirmed by an alternative method, such
as MALDI-TOF MS and thus possibly includes the other
species of the A. baumannii-calcoaceticus complex. The
results obtained in the current study shows the establish-
ment of the species, A. baumannii in our clinical setting.
The OXA-51 cluster is chromosomally encoded and is in-
herent to all A. baumannii isolates [4, 16, 19, 23, 35].
Seven isolates (of which six isolates were excluded) did
not have the inherent OXA-51 gene. These isolates were
further analysed using MALDI-TOF, which identified the
seven isolates as: A. baumannii; A. pittii; K. pneumoniae;
Pseudomonas putida (2x); Staphylococcus aureus and S.
epidermidis. Studies have shown that the detection of the
blaOXA-51-like gene can be used as a simple and reliable
way of identifying A. baumannii [36, 37]. Although it is
clear that blaOXA-51-like genes are present in at least the
vast majority of isolates of A. baumannii, there has
been some debate as to whether they are present in all
isolates of this species [36]. Zander et al. [38] reported
that three A. baumannii isolates did not harbour the
predicted blaOXA-51-like gene (353 bp) and instead amp-
lified PCR products of 1.2 kb and 1.6 kb. The authors
then used external primers and the amplicons revealed
that the one isolate (Ab-511) possessed the blaOXA-51
variant blaOXA-66, which was interrupted by the inser-
tion sequence ISAba15 at nucleotide number 435,
while the two other isolates (Ab-508 and Ab-653)
possessed the blaOXA-51 variant blaOXA-78, which was
disrupted at nucleotide number 379 by a novel inser-
tion sequence ISAba19 [38]. Further investigation of
the genomic environment of the isolate identified as A.
baumannii by MALDI-TOF will reveal the changes in
the OXA-51 genetic structure. Additionally the 16S-
23S ribosomal spacer region can be sequenced for fur-
ther species confirmation [37].
The occurrence of the OXA-23 gene has been reported
since 1985 in A. baumannii isolates and has now dissemi-
nated worldwide [5, 19, 39, 40]. The prevalence of OXA-23
in this study was 77 %, compared to Kock et al. [5], who re-
ported a 59 % prevalence in the same clinical setting in
2008. It is clear that the prevalence of OXA-23 in A. bau-
mannii isolates in this clinical setting is increasing. This in-
creased occurrence can be due to poor infection control
practices, spread through contact with healthcare workers
or from patient to patient and prolonged antibiotic use
[11]. Stricter adherence to infection prevention and control
policies by healthcare workers are needed to prevent fur-
ther dissemination [4, 41, 42]. Correct use of disinfectants
and solutions containing ethanol is particularly important
because if applied at very low concentrations A. baumannii
bacterium can become more pathogenic [41].
The high prevalence of OXA-23 can be due to the ac-
quisition of genetic elements, such as plasmids and
transposons [1, 42]. Liakopoulos et al. [43] conducted a
study in 2010 to 2011 and reported a 95 % prevalence of




1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
39 R R R R R R R R R R S R R S R S R
15 R R R R R R R R R R S S R S R S R
14 R R R R R R R R R R S R S S R S R
7 R R R R R R S S S S S S S S R S S
5 R R R R R R R R R R R R R S R S R
2 R R R R R R R R R R S I R S R S R
2 R R R R R R R R R R S S R I R S R
2 R R R R R R R R R R I R R S R S R
1 R R R R R R S S S S S S S S R S R
1 R R R R R R S S S S S S I S R S S
1 R R R R R R R R S S S R R S R S R
1 R R R R R R R R R R R S I S R S R
1 R R R R R R R R I I R R R S R S R
1 R R R R R R R R R R S R I S R S R
1 R R R R R R R R S S S S R S R S R
1 R R R R R R I R S S S S I S R S S
R = resistant; S = susceptible; I = intermediate resistant
Antimicrobial agents: 1 = Ampicillin; 2 = Amoxicillin/Clavulanic acid; 3 = Cefuroxime; 4 = Cefuroximine Axetil; 5 = Cefoxitin; 6 = Cefotaxime; 7 = Ceftazidime; 8 =
Cefepime; 9 = Imipenem; 10 = Meropenem; 11 = Amikacin; 12 = Gentamicin; 13 = Ciprofloxacin; 14 = Tigecycline; 15 = Nitrofurantoin; 16 = Colistin; 17 =
Trimethoprim/Sulfamethoxazole
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OXA-23 in Greece. The OXA-23 cluster can be located
on a plasmid or chromosome [5]. Mugnier et al. [44]
reported in 2010 that eleven isolates had the blaOXA-23
gene on the chromosome, nine isolates had the blaOXA-23
gene on a plasmid and one isolate had two copies of the
blaOXA-23 gene, one on the plasmid and one on the
chromosome. The OXA-23 enzyme has a higher affinity
to hydrolyse imipenem than meropenem, ertapenem or
doripenem [19]. The MDR A. baumannii isolates in this
study that contained the OXA-23 gene showed a 69 %
resistance to imipenem (1 % had intermediate suscepti-
bility and 6 % were susceptible to imipenem). Imipe-
nem susceptibility may be explained by the absence of
the ISAbaI element upstream of the blaOXA-23 gene
[45]. Twenty-two percent of the isolates were positive


































Fig. 1 The percentage of antibiotic resistance in clinical A. baumannii isolates in 2008 and 2013 in the Pretoria region
Fig. 2 Results obtained after the M-PCR I assay, using a 1.8% (m/v) Metaphor agarose gel electrophoresis for the detection of oxacillinase (OXA)
genes in A. baumannii isolates. The M-PCR assay amplified the OXA-23 (501 bp) and OXA-51 (353 bp) genes. Lanes 3, 5 and 7 were negative for
all of the OXA genes. Lanes 2, 4, 8, 9, 10, 11 and 12 were positive for OXA-23 and OXA-51. Lane 6 was positive for OXA-51 only. Lane 1 was the
negative control. Lane “L” represented the O’Range Ruler™ 100 bp DNA ladder
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isolates were resistant to imipenem while 5 % were
susceptible.
The prevalence rates of isolates that contained both
the OXA-23 and OXA-51 genes were 77 %. It is evident
that the carbapenem-hydrolysing class D β-lactamases
(CHDL’s), such as OXA-23 and OXA-51 were prevalent
in clinical A. baumannii isolates in this study. The high
prevalence of the OXA-51 and OXA-23 group (77 %) is
due to the spread and establishment of several successful
clones in our clinical setting.
None of the clinical A. baumannii isolates contained the
genes that were screened for in M-PCR II to IV as well as
the OXA-24 and OXA-58 genes that were part of M-PCR I.
The GIM, SIM and SPM metallo-β-lactamase (MBL) genes
are rarely found in A. baumannii isolates [46]. Kock et al.
[5] reported one A. baumannii isolate that was positive for
the VIM-like gene. Safari et al. [47] reported that 99 % of
the isolates in ICU wards of three educational hospitals of
Hamadan City in Iran produced metallo-β-lactamases. In
2013, the first outbreak of NDM-1 producing A. baumannii
was reported in France, which occurred in a surgical ICU
[48]. Fortunately NDM-1 in A. baumannii has not yet been
detected in our clinical setting. The NDM-1 gene encodes
an MBL carbapenemase that has a high hydrolytic activity
for carbapenem antibiotics, and much more [49].
PFGE is suited for studying isolates from a defined tem-
poral and spatial epidemiologic setting, whereas MLST
has an advantage in defining clonal lineages of isolates
from larger geographic areas over time [50]. Three clonal
lineages of A. baumannii, commonly referred to as the
pan-European clonal lineages (EUI, EUII, and EUIII), have
predominated in many European countries since the
1990s [50]. Isolates belonging to the pan-European clonal
lineages I and II (EUI and EUII) were identified in our
clinical setting. EUI (ST258 and ST758) was predominant
together with the OXA-23 gene. Other diverse clones,
such as ST106 and ST339 are also circulating in our clin-
ical setting. The origin of the A. baumannii isolates in our
setting cannot be attributed to the dissemination of one or
two successful clones but rather to the dissemination of a
diverse group of successful clones.
Conclusions
The increasing resistance to carbapenems are of great con-
cern due to the limited number of effective drugs and the
Isolate ST blaOXA-23
Fig. 3 PFGE patterns of A. baumannii isolates. The bandings patterns
were analysed using the GelCompar II software programme (GelCompar
II, Applied Maths, Belgium). A distance matrix was constructed using the
Dice coefficient and a dendogramme was constructed from the distance
matrix using UPGMA. Major pulsotype designation was based on five or
more isolates showing ≥80 % relatedness. Isolate name, ST and the
carriage of blaOXA-23 (Y, positive; N, negative) are indicated
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association with increased morbidity and mortality. There
was a noticeable change in the resistance profiles of
the A. baumannii isolates from 2008 to 2013 in the same
setting. The high prevalence of MDR A. baumannii isolates
has a severe impact on treatment outcomes in the studied
healthcare facilities. The presence of the OXA-23 gene was
not related to a specific ST and can be due to the acquisi-
tion of genetic elements, such as plasmids and transposons.
OXA-23 and ST758 were dominant among the isolates. A
limitation of this study is the small sample size and only
tertiary academic hospitals in the Pretoria region were in-
cluded and thus the findings in this study are not a true
reflection of the situation in the whole of SA. Another limi-
tation of this study is that there were not any positive con-
trols included for the screened genes in M-PCR assay III,
which could have caused that these genes were missed due
to not using the optimal PCR conditions.
It is vital to identify and characterise healthcare-
associated pathogens and their circulating antibiotic re-
sistance genes as it is of great concern to public health
systems. Understanding the resistance genes can lead
to the understanding of their origin and can assist in
better infection control measures and ultimately limit
the spread of these pathogens.
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